IMGENEX Corporation, a San Diego based company, has obtained exclusive world-wide rights to US Patent no. 5,830,451 from Brigham & Women’s Hospital, Boston, to develop and market the EBI3-p35 fusion protein also known as Interleukin 35 (IL-35), for research purposes. IL-35 is a novel IL-12 family cytokine produced by regulatory T cells (Treg) shown to suppress immune response through...
SanDiego,CA- August 25, 2007 – IMGENEX is pleased to announce that it has signed an exclusive distribution agreement with Dendritics SAS (Dardilly, France) to make their portfolio of highly characterized and validated monoclonal Dendritic cell research antibodies available to researchers in North America and India. Founded in 2005, the goal of Dendritics SAS was to make their technology and...
San Diego, CA – August 25, 2007 – IMGENEX is excited to announce the availability of patient survival data for 25 of their most popular slides. This information will enable researchers to identify important prognostic markers and biomarker clusters for characterization of disease progression and patient outcome. Tissue microarrays (TMA) are a high-throughput method for investigating...